Biogen to Acquire Reata Pharmaceuticals
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy…
Browsing Tag
Biogen Inc
Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the…
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and…
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease New data on subcutaneous formulation…
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of…
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesEli Lilly on Monday said it applied for full U.S. Food and Drug…
Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors…
The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersMedicare has agreed to pay for the Alzheimer's treatment…
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson…
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of…
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for…
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older…
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants…
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world…
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI®…
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s…